PDCD1 and colorectal carcinoma: In a large combination immunotherapy study, the CheckMate-142 trial, 119 MSI-H/dMMR CRC patients were treated with Ipilimumab combined with the PD-1 inhibitor Nivolumab and had an investigator-assessed ORR of 55% (95% CI, 45.2-63.8) and a 12-week disease control rate of 80%.